Cepheid to Webcast Upcoming Financial Presentations

SUNNYVALE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.


Baird Health Care Conference, New York, NY


Wednesday, September 15, 2010 at 10.30 a.m. Eastern Time




Stifel Nicolaus Healthcare Conference, Boston, MA


Thursday, September 16, 2010 at 10.55 a.m. Eastern Time




UBS Global Life Sciences Conference, New York, NY


Tuesday, September 21, 2010, 10.30 a.m. Eastern Time





To access the live webcast for these events, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.



CONTACTS:




For Media Inquiries:

For Investor Inquiries:



Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400-8377

jared.tipton@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400-8329

investor.relations@cepheid.com






SOURCE Cepheid

Back to news